Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PRNP | P04156 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851116 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1MAPTNCEH1 | |
| SCHEMBL3913701 | 0.85 | ALDH1A1 (0.32) | MAPTHPGD | |
| SCHEMBL3846549 | 0.85 | ALDH1A1 (0.32) | MAPTHPGD | |
| SCHEMBL3566608 | 0.83 | NQO2 (0.35) | SMN1; SMN2RAB9ANPC1NQO2 | |
| SCHEMBL3566612 | 0.83 | NQO2 (0.35) | SMN1; SMN2RAB9ANPC1NQO2 | |
| SCHEMBL3559269 | 0.83 | NCEH1 (0.39) | NCEH1 | |
| SCHEMBL3562268 | 0.83 | NQO2 (0.35) | SMN1; SMN2RAB9ANPC1MAPTLMNA | |
| SCHEMBL3562270 | 0.83 | NQO2 (0.35) | SMN1; SMN2RAB9ANPC1MAPTLMNA | |
| SCHEMBL3559265 | 0.83 | NCEH1 (0.39) | NCEH1 | |
| SCHEMBL3568300 | 0.83 | LCK (0.39) | NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-8017640-B2 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | UNIVERSITY OF BRADFORD (GB) | 2011-09-13 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| EP-1809603-A4 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2009-09-02 | — | — | EP | disclosed |
| EP-1809603-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2007-07-25 | — | — | EP | disclosed |
| US-20070161669-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | SCHOOL OF PHARMACY UNIVERSITY OF LONDON | 2007-07-12 | — | — | US | disclosed |
| US-7192977-B2 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | SCHOOL OF PHARMACY (GB) | 2007-03-20 | — | — | US | disclosed |
| WO-2006043839-A1 | NITROBENZINDOLES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-04-27 | — | — | WO | disclosed |
| US-20040138246-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | INCANTHERA LIMITED (GB) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161669-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | CYP1B1, CYP1A1, RECQL | SMN1; SMN2 4316/4885RAB9A 2459/4885NPC1 3797/4885 |
| US-20040138246-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | CYP1B1, CYP1A1, UGT1A1 | SMN1; SMN2 4413/4885RAB9A 2496/4885NPC1 3312/4885 |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | DBI, CCNI, TDO2 | SMN1; SMN2 1826/4885RAB9A 3688/4885NPC1 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.